Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Tarceva now was established first-line therapy for advanced lung adenocarcinoma with mutant
EGFR patients.However,the benefit lasted for about 6-8 months.So we consider to add
apatinib,a tyrosine kinase inhibitor of VEGF,to the therapy of these patients.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Kunming Medical College